- Report
- June 2026
- 200 Pages
Global
From €2749EUR$2,990USD£2,343GBP
- Report
- February 2026
- 250 Pages
Global
From €4127EUR$4,490USD£3,518GBP
- Report
- February 2026
- 250 Pages
Global
From €4127EUR$4,490USD£3,518GBP
- Report
- October 2026
- 282 Pages
Global
From €5378EUR$5,850USD£4,583GBP
- Report
- February 2026
- 200 Pages
Global
From €7345EUR$7,990USD£6,260GBP
- Report
- November 2023
- 135 Pages
Global
From €3677EUR$4,000USD£3,134GBP
- Report
- June 2025
- 150 Pages
Global
From €3447EUR$3,750USD£2,938GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1379EUR$1,500USD£1,175GBP
- Report
- December 2024
- 30 Pages
Global
From €2528EUR$2,750USD£2,155GBP
- Report
- September 2024
- 343 Pages
Global
From €7308EUR$7,950USD£6,229GBP
- Report
- July 2024
- 150 Pages
Global
From €3447EUR$3,750USD£2,938GBP
- Report
- June 2025
- 400 Pages
Global
From €4549EUR$4,949USD£3,877GBP
- Report
- March 2023
- 147 Pages
Global
From €4549EUR$4,949USD£3,877GBP
- Report
- May 2024
- 137 Pages
Global
From €3676EUR$3,999USD£3,133GBP
- Report
- May 2024
- 135 Pages
Global
From €3676EUR$3,999USD£3,133GBP
- Report
- January 2023
- 85 Pages
Europe
From €1379EUR$1,500USD£1,175GBP
- Report
- September 2025
- 150 Pages
Global
From €4091EUR$4,450USD£3,486GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,079USD£3,087GBP
- Report
- January 2024
- 156 Pages
United States
€3493EUR$3,800USD£2,977GBP
- Report
- January 2024
- 114 Pages
United States
€3217EUR$3,500USD£2,742GBP

Tiotropium is a long-acting anticholinergic drug used to treat chronic obstructive pulmonary disease (COPD). It is a bronchodilator, meaning it relaxes the muscles in the airways, allowing more air to flow in and out of the lungs. It is available in both an inhaler and a dry powder inhaler. Tiotropium is the only long-acting anticholinergic approved for the treatment of COPD. It is also used to treat asthma and other respiratory conditions.
Tiotropium is a popular drug in the respiratory drugs market, as it is effective in treating COPD and other respiratory conditions. It is also well-tolerated, with few side effects. It is available in both generic and brand-name forms, making it accessible to a wide range of patients.
Some companies in the Tiotropium market include Boehringer Ingelheim, GlaxoSmithKline, and Novartis. Show Less Read more